UY38514A - Inhibidores de apol1 y sus métodos de uso - Google Patents
Inhibidores de apol1 y sus métodos de usoInfo
- Publication number
- UY38514A UY38514A UY0001038514A UY38514A UY38514A UY 38514 A UY38514 A UY 38514A UY 0001038514 A UY0001038514 A UY 0001038514A UY 38514 A UY38514 A UY 38514A UY 38514 A UY38514 A UY 38514A
- Authority
- UY
- Uruguay
- Prior art keywords
- apol1
- inhibitors
- use methods
- methods
- ndkd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780667P | 2018-12-17 | 2018-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38514A true UY38514A (es) | 2020-07-31 |
Family
ID=69182627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038514A UY38514A (es) | 2018-12-17 | 2019-12-17 | Inhibidores de apol1 y sus métodos de uso |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11618746B2 (https=) |
| EP (1) | EP3897833B1 (https=) |
| JP (1) | JP7573528B2 (https=) |
| KR (2) | KR102912203B1 (https=) |
| CN (1) | CN113453760B (https=) |
| AR (1) | AR116913A1 (https=) |
| AU (1) | AU2019405477B2 (https=) |
| CA (1) | CA3121910A1 (https=) |
| CL (1) | CL2021001561A1 (https=) |
| CO (1) | CO2021009053A2 (https=) |
| CR (1) | CR20210383A (https=) |
| DK (1) | DK3897833T3 (https=) |
| DO (1) | DOP2021000116A (https=) |
| EC (1) | ECSP21052184A (https=) |
| FI (1) | FI3897833T3 (https=) |
| IL (2) | IL283592B2 (https=) |
| JO (3) | JOP20210131A1 (https=) |
| MA (1) | MA54538A (https=) |
| MX (1) | MX2021007152A (https=) |
| PE (1) | PE20212302A1 (https=) |
| SA (1) | SA521422270B1 (https=) |
| SG (1) | SG11202105769XA (https=) |
| TW (1) | TWI848031B (https=) |
| UA (1) | UA128375C2 (https=) |
| UY (1) | UY38514A (https=) |
| WO (1) | WO2020131807A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI848031B (zh) | 2018-12-17 | 2024-07-11 | 美商維泰克斯製藥公司 | Apol1抑制劑及其使用方法 |
| WO2021154997A1 (en) * | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| CA3173808A1 (en) | 2020-03-06 | 2021-09-10 | Vertex Pharmaceuticals Incorporated | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CA3185604A1 (en) * | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| WO2021252849A1 (en) * | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| WO2021252863A1 (en) * | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
| IL300298B2 (en) * | 2020-08-26 | 2025-06-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| CN116997546A (zh) * | 2021-02-19 | 2023-11-03 | 梅兹治疗公司 | Apol1抑制剂及使用方法 |
| MX2024002229A (es) * | 2021-08-26 | 2024-05-15 | Vertex Pharma | Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas. |
| CA3240523A1 (en) * | 2021-11-30 | 2023-06-08 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| IL314330A (en) | 2022-01-18 | 2024-09-01 | Maze Therapeutics Inc | Apol1 inhibitors and methods of use |
| CN119343353A (zh) * | 2022-02-08 | 2025-01-21 | 弗特克斯药品有限公司 | 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 |
| WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
| US20260055083A1 (en) * | 2022-08-19 | 2026-02-26 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
| WO2025006262A1 (en) * | 2023-06-29 | 2025-01-02 | Omniab, Inc. | Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease |
| GB202401326D0 (en) * | 2024-02-01 | 2024-03-20 | Podium Bio Ltd | Novel compounds |
| KR20250122547A (ko) | 2024-02-05 | 2025-08-14 | 서주사이언티픽 주식회사 | AIoT 기반 방사성 동위원소 관리 시스템 |
| WO2026012338A1 (zh) * | 2024-07-09 | 2026-01-15 | 上海旭成医药科技有限公司 | 一种APOLs抑制剂 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039676A (en) | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
| EP0934941A1 (en) | 1996-08-09 | 1999-08-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| DE69814012T2 (de) | 1997-12-19 | 2004-04-01 | Eli Lilly And Co., Indianapolis | Hypoglykàmische imidazoline derivate |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| WO2001017965A2 (en) | 1999-09-07 | 2001-03-15 | Syngenta Participations Ag | Cyanopiperidines as pesticides |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| CA2424222A1 (en) | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| MXPA04004657A (es) | 2001-11-14 | 2004-08-13 | Teva Pharma | Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion. |
| AU2003237593A1 (en) * | 2002-06-05 | 2003-12-22 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| CA2537349A1 (en) | 2003-09-03 | 2005-03-10 | Galapagos Nv | The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders |
| WO2005092854A1 (en) | 2004-03-03 | 2005-10-06 | Eli Lilly And Company | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators |
| AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| AU2006316321A1 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| EP2086935A1 (de) | 2006-10-16 | 2009-08-12 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
| EP2097376A2 (en) | 2006-12-22 | 2009-09-09 | F. Hoffmann-Roche AG | Spiro-piperidine derivatives |
| WO2008092231A1 (en) * | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| CN101801965B (zh) | 2007-08-17 | 2014-07-30 | 株式会社Lg生命科学 | 作为细胞坏死抑制剂的吲哚化合物 |
| EP2435407B1 (en) | 2009-05-29 | 2019-12-25 | RaQualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| UA107943C2 (xx) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| ES2436241T3 (es) | 2009-11-16 | 2013-12-27 | Eli Lilly And Company | Compuestos de espiropiperidina como antagonistas de receptor oral-1 |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| BR102012024778A2 (pt) | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| JP2016531874A (ja) * | 2013-09-26 | 2016-10-13 | ファーマケア，インク． | オートタキシン阻害剤化合物 |
| ES2895490T3 (es) | 2014-03-27 | 2022-02-21 | Acad Medisch Ct | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| EP3186225A4 (en) | 2014-08-27 | 2018-02-28 | The Governing Council of the University of Toronto | Cannabinoid type 1 receptor modulators |
| JP2017536342A (ja) | 2014-10-08 | 2017-12-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物 |
| TW201632522A (zh) | 2014-11-21 | 2016-09-16 | 伊史帝夫博士實驗室股份有限公司 | 針對疼痛具有多模式活性的螺－異喹啉－１，４’－哌啶化合物 |
| ES2865199T3 (es) | 2015-08-27 | 2021-10-15 | Pfizer | Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4 |
| JP6990657B2 (ja) | 2016-02-08 | 2022-01-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｄｄｒ１阻害剤としてのスピロインドリノン |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| MA53924A (fr) | 2018-05-22 | 2021-08-25 | Ionis Pharmaceuticals Inc | Modulateurs de l'expression d'apol1 |
| TWI848031B (zh) | 2018-12-17 | 2024-07-11 | 美商維泰克斯製藥公司 | Apol1抑制劑及其使用方法 |
| US20220144838A1 (en) | 2019-03-13 | 2022-05-12 | Nanjing Immunophage Biotech Co., Ltd. | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor |
| TW202136219A (zh) | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| CA3173808A1 (en) * | 2020-03-06 | 2021-09-10 | Vertex Pharmaceuticals Incorporated | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| AU2021259580A1 (en) | 2020-04-22 | 2022-11-24 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
| WO2021224927A1 (en) | 2020-05-07 | 2021-11-11 | Rambam Med-Tech Ltd. | Composition for use in the treatment of apol1-associated disease |
| WO2021252863A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
| WO2021252849A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| IL300298B2 (en) | 2020-08-26 | 2025-06-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| MX2024002229A (es) | 2021-08-26 | 2024-05-15 | Vertex Pharma | Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas. |
| CA3240523A1 (en) | 2021-11-30 | 2023-06-08 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| JP2025505645A (ja) | 2022-02-08 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｐｏｌ１の阻害剤としてのスピロピペリジン誘導体およびその使用方法 |
| EP4476228A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| AU2023219516A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| CN119343353A (zh) | 2022-02-08 | 2025-01-21 | 弗特克斯药品有限公司 | 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 |
-
2019
- 2019-12-17 TW TW108146307A patent/TWI848031B/zh active
- 2019-12-17 UA UAA202104153A patent/UA128375C2/uk unknown
- 2019-12-17 AR ARP190103717A patent/AR116913A1/es unknown
- 2019-12-17 PE PE2021000896A patent/PE20212302A1/es unknown
- 2019-12-17 CR CR20210383A patent/CR20210383A/es unknown
- 2019-12-17 UY UY0001038514A patent/UY38514A/es active IP Right Grant
- 2019-12-17 KR KR1020217022550A patent/KR102912203B1/ko active Active
- 2019-12-17 JP JP2021534284A patent/JP7573528B2/ja active Active
- 2019-12-17 EP EP19839496.7A patent/EP3897833B1/en active Active
- 2019-12-17 US US16/717,099 patent/US11618746B2/en active Active
- 2019-12-17 IL IL283592A patent/IL283592B2/en unknown
- 2019-12-17 MA MA054538A patent/MA54538A/fr unknown
- 2019-12-17 CN CN201980092356.3A patent/CN113453760B/zh active Active
- 2019-12-17 SG SG11202105769XA patent/SG11202105769XA/en unknown
- 2019-12-17 MX MX2021007152A patent/MX2021007152A/es unknown
- 2019-12-17 AU AU2019405477A patent/AU2019405477B2/en active Active
- 2019-12-17 CA CA3121910A patent/CA3121910A1/en active Pending
- 2019-12-17 DK DK19839496.7T patent/DK3897833T3/da active
- 2019-12-17 FI FIEP19839496.7T patent/FI3897833T3/fi active
- 2019-12-17 JO JOP/2021/0131A patent/JOP20210131A1/ar unknown
- 2019-12-17 IL IL319575A patent/IL319575A/en unknown
- 2019-12-17 KR KR1020267000658A patent/KR20260020195A/ko active Pending
- 2019-12-17 WO PCT/US2019/066746 patent/WO2020131807A1/en not_active Ceased
-
2021
- 2021-06-03 JO JOP/2021/0129A patent/JOP20210129A1/ar unknown
- 2021-06-03 JO JOP/2021/0130A patent/JOP20210130A1/ar unknown
- 2021-06-15 CL CL2021001561A patent/CL2021001561A1/es unknown
- 2021-06-15 DO DO2021000116A patent/DOP2021000116A/es unknown
- 2021-06-15 SA SA521422270A patent/SA521422270B1/ar unknown
- 2021-07-09 CO CONC2021/0009053A patent/CO2021009053A2/es unknown
- 2021-07-15 EC ECSENADI202152184A patent/ECSP21052184A/es unknown
-
2023
- 2023-02-07 US US18/106,569 patent/US12060346B2/en active Active
-
2024
- 2024-06-17 US US18/745,762 patent/US20250042878A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21052184A (es) | Inhibidores de apol1 y sus métodos de uso | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| MX2022014548A (es) | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| DOP2023000041A (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
| CL2020003378A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| CL2023000662A1 (es) | Agentes de rnai para inhibir la expresión de dux4, composiciones de los mismos y métodos de uso. | |
| BR112017002594A2 (pt) | compostos inibidores de cinase de ligação de tank | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| PT4222152T (pt) | Compostos de carbamoilpiridona tricíclica com ponte para uso no tratamento do hiv | |
| ECSP099027A (es) | Anticuerpos anti-dll4 y métodos que los usan | |
| CR10069A (es) | Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2022001452A1 (es) | Inhibidores de masp-2 y métodos de uso. | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| DK3962601T3 (da) | 5-HT2A-agonister til anvendelse til behandling af depression | |
| CR20200631A (es) | Modulares de la expresión de apol1 | |
| CR20200089A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
| AR111431A1 (es) | Combinaciones de fungicidas | |
| CO2026004176A2 (es) | Degradadores de stat6 y usos de los mismos | |
| ES2609817T3 (es) | Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida | |
| MX2022000654A (es) | Sistemas fluorescentes para imagenes biologicas y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 110 | Patent granted |
Effective date: 20260126 |